Examples of Publications in Different Areas:

1.  Inflammation and cardiovascular disease

Asanuma Y, Oeser A, Shintani A, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary artery atherosclerosis in systemic lupus erythematosus.  New England Journal of Medicine 2003;349:2407-15.

Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani A,  Sokka T, Pincus T, Avalos I, Stein CM. Increased coronary artery atherosclerosis in rheumatoid arthritis: relationship with disease duration and cardiovascular risk factors. Arthritis and Rheumatism 2005; 3045-3053.

Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Stein CM. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis and Rheumatism 2008, 58: 2105-12. PMID: 18576352, (PMC 2755593).

Bradham B, Bian A, Oeser A, Gebretsadik T, Shintani A, Solus J,  Estis J, Lu Q, Todd J, Raggi P, Stein CM, High-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammation. PLoS ONE, June 2012; 7 (6), e38930.  (PMC3386265)

Ormseth, MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM, Bian A, Gebretsakik T, Shintani A, Raggi P, Stein CM.  Epicardial adipose tissue is associated with cardiometabolic risk and the metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res 2013 Apri 16.  PMID: 23592527
6.  Ormseth MJ, Oeser AM, Cunningham A, Bian A, Shintani A, Solus J, Tanner SB, Stein CM. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res Ther. 2013 Sep 10;15(5):R110. [Epub ahead of print] PMID: 24020899.

2. Cardiovascular pharmacogenetics

Dishy V, Sofowora G, Xie HG, Byrne D, Kim RB, Stein CM, Wood AJJ. The effect of common polymorphisms of the beta-2 adrenergic receptor on agonist-mediated vascular desensitization in vivo.  New England Journal of Medicine 2001:345;1030-5

Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, Xie HG, Harris PA, Williams SM, Nair UB, Wood AJ, Stein, CM. β1-adrenoceptor genetic variants and ethnicity independently affect response to β-blockade. Pharmacogenetics and Genomics 2008 Oct;18(10):895-902. (PMC2757009)

Kurnik D, Muszkat M, Li C, Sofowora GG, Friedman EA, Scheinin M,  Wood AJ, Stein CM. Genetic variations in the α2A-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. Circulation Cardiovascular Genetics 2011;4: 179-87.   (PMC3080459)

Adefurin A, Ghimire LV, Kohli U, Muszkat M, Sofowora GG, Paranjape SY, Stein CM, Kurnik D. Blacks have a greater sensitivity to α1-adrenoceptor-mediated venoconstriction compared with whites. Hypertension. 2013 Apr;61(4):915-20.PMID: 23399717. (PMC3627527)

Posti JP, Salo P, Ruohonen S, Valve L, Muszkat M, Sofowora GG, Kurnik D, Stein CM, Perola M, Scheinin M, Snapir A. A polymorphism in the protein kinase C gene PRKCB is associated with α2-adrenoceptor-mediated vasoconstriction. Pharmacogenetics and Genomics. 2013:23:127-34. PMID: 23337848

3. Drug metabolism pharmacogenetics

Schwarz UI, Ritchie MD, Bradford Y, Li Chun, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation.  New England Journal of Medicine 2008;358:999-1008. PMID: 18322281.

The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine 2009; 360:753-64. (PMC2722908)

Li C, Schwarz UI, Ritchie M, Roden DM, Stein CM, Kurnik, D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009;113:3925-30  (PMC2673121).

Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics and Genomics. 2011 Nov 19. PMID 22108237. (PMC3237759)

Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6(11):e27808. (PMC3218053).

Choi L, Caffo BS, Kohli U, Pandharipande P, Kurnik D, Ely EW, Stein CM. A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2011:38:613-36 (PMC3182101)

4. Drug Safety

Ray WA, Stein CM, Daugherty JR, Hall K, Abrogast PG, Griffin MR. COX-2 selective NSAIDs and the risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.

Ray WA, Chung CP, Murray KT, Hall K, Stein CM.   Atypical antipsychotics and the risk of sudden death from cardiac causes. New England Journal of Medicine 2009; 360:225-35. (PMC2713724)

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine 2011; 365: 1896-1904. PMID: 2043968.

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. New England Journal of Medicine 2012; 366:1881-90. PMID:22591294 (PMC3374857)

Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, Fuchs DC, Ray WA. Antipsychotics and the risk of Type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013; 70: 1067-1075. PMID: 23965896  (non-NIH funded)